Abstract
Indole derivative 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4. The 4-fluoro derivative 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution formulation. However, aqueous suspensions of 2 were poorly bioavailable, indicative of dissolution-limited absorption. The 7-azaindole derivative 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.
MeSH terms
-
Administration, Oral
-
Animals
-
Anti-HIV Agents / pharmacokinetics
-
Anti-HIV Agents / pharmacology*
-
Biological Availability
-
CCR5 Receptor Antagonists
-
CD4 Antigens / metabolism*
-
Dogs
-
HIV Envelope Protein gp120 / metabolism*
-
HIV-1 / drug effects*
-
HIV-1 / metabolism*
-
Humans
-
Indoles / chemistry
-
Indoles / pharmacokinetics
-
Indoles / pharmacology*
-
Infusions, Intravenous
-
Macaca fascicularis
-
Piperazines / chemistry
-
Piperazines / pharmacokinetics
-
Piperazines / pharmacology*
-
Rats
-
Receptors, CXCR4 / antagonists & inhibitors
Substances
-
1-(4-benozylpiperazin-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione
-
Anti-HIV Agents
-
BMS-378806
-
CCR5 Receptor Antagonists
-
CD4 Antigens
-
HIV Envelope Protein gp120
-
Indoles
-
Piperazines
-
Receptors, CXCR4